Quoin Pharmaceuticals, Ltd. (QNRX) Cash Flow Statement
Quoin Pharmaceuticals, Ltd. (QNRX) generated -$15.3M of operating cash flow over the twelve months to 2026-06-30, spent $0 on capital expenditure and had free cash flow of -$15.3M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
QNRXQuoin Pharmaceuticals, Ltd.Follow QNRX — free
—
Price chart with a free account
- Market cap
- 282.6M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -5.7 | -8.5 | -7.9 | -7.9 | -13.5 | -15.3 | |
| Capital expenditure | — | — | — | 0.0 | 0.0 | -0.0 | |
| Free cash flow | — | — | — | -7.9 | -13.5 | -15.3 | |
| Stock-based compensation | — | 0.8 | 1.1 | 1.3 | 1.1 | — |
USD millions · SEC XBRL
Quoin Pharmaceuticals, Ltd. — questions
- What is Quoin Pharmaceuticals, Ltd.'s operating cash flow?
- -$15.3M over the twelve months to 2026-06-30.
- How much does Quoin Pharmaceuticals, Ltd. spend on capital expenditure?
- $0 over the twelve months to 2026-06-30.
- What is Quoin Pharmaceuticals, Ltd.'s free cash flow?
- -$15.3M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Quoin Pharmaceuticals, Ltd.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.